139 related articles for article (PubMed ID: 28696420)
1. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.
Moretti ME; Lato DF; Berger H; Koren G; Ito S; Ungar WJ
Pharmacogenomics J; 2018 May; 18(3):391-397. PubMed ID: 28696420
[TBL] [Abstract][Full Text] [Related]
2. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine.
Madadi P; Ciszkowski C; Gaedigk A; Leeder JS; Teitelbaum R; Chitayat D; Koren G
Curr Drug Saf; 2011 Feb; 6(1):36-9. PubMed ID: 21241245
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
7. A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.
Berm EJ; Gout-Zwart JJ; Luttjeboer J; Wilffert B; Postma MJ
PLoS One; 2016; 11(12):e0169065. PubMed ID: 28033366
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P; Ross CJ; Hayden MR; Carleton BC; Gaedigk A; Leeder JS; Koren G
Clin Pharmacol Ther; 2009 Jan; 85(1):31-5. PubMed ID: 18719619
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
Reynolds KK; McNally BA; Linder MW
Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
[TBL] [Abstract][Full Text] [Related]
11. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine.
Madadi P; Koren G; Cairns J; Chitayat D; Gaedigk A; Leeder JS; Teitelbaum R; Karaskov T; Aleksa K
Can Fam Physician; 2007 Jan; 53(1):33-5. PubMed ID: 17872605
[TBL] [Abstract][Full Text] [Related]
12. Establishing causality of CNS depression in breastfed infants following maternal codeine use.
Madadi P; Shirazi F; Walter FG; Koren G
Paediatr Drugs; 2008; 10(6):399-404. PubMed ID: 18998750
[TBL] [Abstract][Full Text] [Related]
13. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?
Laika B; Leucht S; Heres S; Steimer W
Pharmacogenomics J; 2009 Dec; 9(6):395-403. PubMed ID: 19451914
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.
Alagoz O; Durham D; Kasirajan K
Pharmacogenomics J; 2016 Apr; 16(2):129-36. PubMed ID: 25987241
[TBL] [Abstract][Full Text] [Related]
15. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk.
Kelly LE; Chaudhry SA; Rieder MJ; 't Jong G; Moretti ME; Lausman A; Ross C; Berger H; Carleton B; Hayden MR; Madadi P; Koren G
PLoS One; 2013; 8(7):e70073. PubMed ID: 23922910
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 phenotype-specific codeine population pharmacokinetics.
Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
[TBL] [Abstract][Full Text] [Related]
17. Ethical considerations in CYP2D6 genotype testing for codeine-prescribed breastfeeding mothers.
Kurtz M; Black Golde P; Berlinger N
Clin Pharmacol Ther; 2010 Dec; 88(6):760-2. PubMed ID: 21081947
[TBL] [Abstract][Full Text] [Related]
18. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.
Sistonen J; Madadi P; Ross CJ; Yazdanpanah M; Lee JW; Landsmeer ML; Nauta M; Carleton BC; Koren G; Hayden MR
Clin Pharmacol Ther; 2012 Apr; 91(4):692-9. PubMed ID: 22398969
[TBL] [Abstract][Full Text] [Related]
19. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J
Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640
[TBL] [Abstract][Full Text] [Related]
20. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
